Literature DB >> 33505947

Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable.

Andrea M Coverstone1, Thomas W Ferkol1,2.   

Abstract

Cystic fibrosis is the most common life-shortening genetic disease affecting Caucasians, clinically manifested by fat malabsorption, poor growth and nutrition, and recurrent sinopulmonary infections. Newborn screening programs for cystic fibrosis are now implemented throughout the United States and in many nations worldwide. Early diagnosis and interventions have led to improved clinical outcomes for people with cystic fibrosis. Newer cystic fibrosis transmembrane conductance regulator potentiators and correctors with mutation-specific effects have increasingly been used in children, and these agents are revolutionizing care. Indeed, it is possible that highly effective modulator therapy used early in life could profoundly affect the trajectory of cystic fibrosis lung disease, and primary prevention may be achievable.
Copyright © 2021 Coverstone and Ferkol.

Entities:  

Keywords:  corrector; cystic fibrosis; cystic fibrosis transmembrane conductance regulator; immunoreactive trypsin(ogen); newborn screening; potentiator; sweat chloride test

Year:  2021        PMID: 33505947      PMCID: PMC7830672          DOI: 10.3389/fped.2020.608821

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


  62 in total

1.  Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines.

Authors:  Vicky A LeGrys; James R Yankaskas; Lynne M Quittell; Bruce C Marshall; Peter J Mogayzel
Journal:  J Pediatr       Date:  2007-07       Impact factor: 4.406

2.  Newborn screening showing decreasing incidence of cystic fibrosis.

Authors:  Jaime E Hale; Richard B Parad; Anne Marie Comeau
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

3.  Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.

Authors:  Scott H Donaldson; Beth L Laube; Timothy E Corcoran; Pradeep Bhambhvani; Kirby Zeman; Agathe Ceppe; Pamela L Zeitlin; Peter J Mogayzel; Michael Boyle; Landon W Locke; Michael M Myerburg; Joseph M Pilewski; Brian Flanagan; Steven M Rowe; William D Bennett
Journal:  JCI Insight       Date:  2018-12-20

4.  Normal vas deferens in fetuses with cystic fibrosis.

Authors:  D A Gaillard; F Carré-Pigeon; A Lallemand
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

5.  Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era.

Authors:  Michael J Coffey; Viola Whitaker; Natalie Gentin; Rosie Junek; Carolyn Shalhoub; Scott Nightingale; Jodi Hilton; Veronica Wiley; Bridget Wilcken; Kevin J Gaskin; Chee Y Ooi
Journal:  J Pediatr       Date:  2016-11-10       Impact factor: 4.406

6.  Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; A Laxova; G Shen; R E Koscik; W T Bruns; M Splaingard; E H Mischler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

7.  Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre.

Authors:  F Nicole Dijk; Karen McKay; Federica Barzi; Kevin J Gaskin; Dominic A Fitzgerald
Journal:  Arch Dis Child       Date:  2011-10-12       Impact factor: 3.791

8.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Authors:  Jane C Davies; Claire E Wainwright; Gerard J Canny; Mark A Chilvers; Michelle S Howenstine; Anne Munck; Jochen G Mainz; Sally Rodriguez; Haihong Li; Karl Yen; Claudia L Ordoñez; Richard Ahrens
Journal:  Am J Respir Crit Care Med       Date:  2013-06-01       Impact factor: 21.405

Review 9.  Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.

Authors:  Marie E Egan
Journal:  Curr Opin Pediatr       Date:  2020-06       Impact factor: 2.856

Review 10.  Newborn Screening for CF across the Globe-Where Is It Worthwhile?

Authors:  Virginie Scotet; Hector Gutierrez; Philip M Farrell
Journal:  Int J Neonatal Screen       Date:  2020-03-04
View more
  2 in total

1.  Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.

Authors:  Insa Korten; Elisabeth Kieninger; Linn Krueger; Marina Bullo; Christa E Flück; Philipp Latzin; Carmen Casaulta; Claudia Boettcher
Journal:  Front Pediatr       Date:  2022-04-21       Impact factor: 3.569

2.  The Relation between Vitamin D Level and Lung Clearance Index in Cystic Fibrosis-A Pilot Study.

Authors:  Mihaela Dediu; Ioana Mihaiela Ciuca; Liviu Laurentiu Pop; Daniela Iacob
Journal:  Children (Basel)       Date:  2022-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.